Statin myotoxicity: a review of genetic susceptibility factors.
about
Toxic myopathiesStatin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaEffects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trialRhabdomyolysis after midazolam administration in a cirrhotic patient treated with atorvastatin.Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic VariantsLipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle.Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control StudiesTreatment Options for Statin-Associated Muscle Symptoms.Bringing Bioactive Compounds into Membranes: The UbiA Superfamily of Intramembrane Aromatic Prenyltransferases.Mood, Personality, and Behavior Changes During Treatment with Statins: A Case SeriesPharmacogenomics, lipid disorders, and treatment options.Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.Statin intolerance: diagnosis and remedies.The role of mitochondria in statin-induced myopathy.Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challengeLaboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of StatinsMuscular hypertonicity: a suspected contributor to rheumatological manifestations observed in ambulatory practice.The adjuvant value of Herba Cistanches when used in combination with statin in murine models.Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity.Acute rhabdomyolysis associated with coadministration of levofloxacin and simvastatin in a patient with normal renal function.Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives.Genetic variation in statin intolerance and a possible protective role for UGT1A1.[Statin intolerance and associated muscular dysfunctions].LDL-cholesterol lowering effect of a new dietary supplement: an open label, controlled, randomized, cross-over clinical trial in patients with mild-to-moderate hypercholesterolemia.
P2860
Q27007256-3DEE51CF-219B-4D3B-BC22-7C78BD8D4CB6Q28083004-01FCA129-CD33-49A8-8360-4428DF238523Q28275648-09B564E3-02A9-4B54-BE63-99D513B2E73FQ33988933-0E4382EF-8F4E-47A1-BB63-8C6DC7D138E9Q34047690-D6D61B0C-619A-46D1-B636-C9AFFD5C94F0Q34163351-2AEA2A8E-6C1F-4157-B90E-35C2B2A1F3FDQ34221540-6793889C-B5D8-43B7-BF5C-CB646EBBAA57Q35232279-CF48714B-5C07-4063-BAAC-3E9AEFA5D420Q35501523-87E3A80E-5208-4969-97F3-27A973814069Q35669829-6FA58EB3-B1D7-4C48-BD81-B7FC6B48263AQ36256049-C9D5AE58-F0FE-4EAC-8F9B-9EC3188D6D3BQ36294394-DBDF5C67-BCF9-42BA-9BE7-FF143BE372B5Q37014008-B59D895C-DA1A-4C8D-8B44-DEAFCB36D52CQ37218787-4C546C72-0233-403D-B51E-07AD2BD40459Q38203774-F3BAC45E-63D6-436E-973C-B9B9206B012CQ38228757-FC353D75-ED67-4D99-B4A2-0214574FD652Q38415231-03311707-8E7C-44E1-B21C-4D320A8B0FFFQ38430744-3DF2D615-55D9-40BF-B9EE-39C2AF4B7315Q38492567-4437DA68-2C21-45B9-BF0E-FA16425428FAQ38644316-997DFC64-4AF4-4F34-AFC7-FB050A796CA0Q38924930-2C5B2004-AF6C-4F07-80EB-9557867E071FQ39318070-A8445F1F-41B4-46E1-916E-8EA7B7EFF03BQ41516471-80D4B821-F407-4041-89C2-E24651E228B6Q41526681-0141A9F6-12C0-4E8E-B05E-75D477DEBB13Q41940315-1F4A1101-9E8B-4A83-96B5-58930C6C5400Q44739535-D0AD5EC7-7660-4A0F-BE28-FB9CBEE6B0C0Q50054110-E0C6EFB5-15C1-4D24-BCDB-08F17BD1BDBEQ53649484-21741EC9-09D4-433D-B11E-4261341429F6Q55353903-B1DDD7C3-D3CC-48C9-9A41-CEA8F7017C48
P2860
Statin myotoxicity: a review of genetic susceptibility factors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Statin myotoxicity: a review of genetic susceptibility factors.
@en
type
label
Statin myotoxicity: a review of genetic susceptibility factors.
@en
prefLabel
Statin myotoxicity: a review of genetic susceptibility factors.
@en
P1476
Statin myotoxicity: a review of genetic susceptibility factors.
@en
P2093
F L Mastaglia
P356
10.1016/J.NMD.2013.09.011
P577
2013-09-30T00:00:00Z